An Action Plan For GLP-1 Use

Learning From GLP-1 Research

There are constant updates on using GLP-1s for weight loss, with new research emerging on an ongoing basis.

We use the Scandanavian paper, noted below, which identifies the titration of medication in accordance with :

• Tolerance
• Other medications
• Clinical profile
• Patient history

Our recommended treatment pathway is:

• Check in
• Appropriate blood tests
• Analysis of results
• Action plan in consultation with the patient

Our action plan may include treatment for other metabolic conditions, possibly through other practitioners, and incorporation of physical activity into your daily routine. 

We leave no stone unturned to facilitate your long term success.

Other Things Which Trip You Up?

• Processed foods
• Ignoring bloods or treatment of Deficit
• Not checking in at least annually with your Surgeon or Metabolic Specialist

We have learned over the many years of bariatric surgery and medical weight management, that reaching and maintaining a healthy weight is not a drive through experience.

The paper below shows clear benefits in incorporating physical activity along with GLP-1 medication. This is especially true when going off medication, as weight regain is substantially smaller. (roughly 50% less)

That is why we have always offered an expert team to support every patient who engages with the practice.

Could We Help You?

If you are determined to achieve a healthy weight, we can help. Please contact us for a no cost, no obligation consultation. Our SCOPE certified NP, Shirley Lockie, will provide an assessment and discuss options with you.

If you have more questions, please check in on 3355 2011.

Reference

GLP1 S. B. K. Jensen et al. (2024) Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., . . . Torekov, S. S. (2024).

Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.

EClinicalMedicine, 69, 102475. doi:10.1016/ j.eclinm.2024.102475